Physician profile
Paula Stoddard
NPI 1164007118
$21,837.52
in general payments reported to CMS, 2019-2025
25 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $431 · 2023: $1,205 · 2024: $3,270 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $7,708 · Education: $346 · Travel and Lodging: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,900.00 |
| Food and Beverage | $7,708.30 |
| Education | $345.94 |
| Travel and Lodging | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $14,243.38 | 2021-2025 | Nemluvio, Aklief |
| Abbvie INC. | $2,306.56 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,084.78 | 2023-2025 | Sotyktu |
| Incyte Corporation | $604.95 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $563.47 | 2022-2025 | Tremfya |
| Ucb, INC. | $540.25 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $460.98 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $297.72 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $288.20 | 2023-2025 | |
| Dermavant Sciences, INC. | $246.36 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $226.14 | 2023-2024 | Winlevi, Odomzo, Blu-U |
| Leo Pharma INC. | $174.46 | 2022-2024 | Adbry |
| Pfizer INC. | $169.48 | 2024-2025 | |
| Lilly USA, LLC | $146.56 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $117.42 | 2022-2025 | Otezla, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Arcutis Biotherapeutics, INC. | $58.79 | 2024-2025 | Zoryve |
| Esperion Therapeutics, INC. | $48.75 | 2022 | |
| Organon LLC | $39.37 | 2025 | Vtama |
| Krystal Biotech INC | $30.08 | 2023 | Vyjuvek |
| Lnhc, INC | $26.14 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.82 | 2025 | Jublia |
| Ani Pharmaceuticals, INC. | $21.30 | 2025 | Purified Cortrophin Gel |
| Vyne Pharmaceuticals INC. | $19.90 | 2021 | |
| Journey Medical Corporation | $17.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Stoddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.